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Purpose: Intimal smooth muscle cell (SMC) hyperplasia is a main component of the arterial wall response to injury. We
have investigated the capacity of a water-soluble nonanticoagulant functionalized dextran (E9) in inhibition of SMC
growth in vitro and in vivo.
Methods: E9 was obtained with chemical substitutions with anionic and hydrophobic groups on the dextran backbone.
SMC proliferation (cell counting, thymidine uptake, cell cycle analysis) was followed in culture in the presence of E9.
Western blot analysis against phosphorylated mitogen-activated protein kinase (MAPK), extracellular signal-regulated
protein kinase 1/2, and assessment of MAPK activity on serum-stimulated SMCs also were investigated. Binding/
displacement experiments, electron microscopy, and cell fractionations were used to follow the binding and internaliza-
tion of radiolabeled and fluorescentlabeled E9. New Zealand white rabbit iliac arteries were injured with balloon
dilatation and stent deployment. Animals were treated for 14 days with saline solution or E9 (5 mg/kg injected
subcutaneously, twice daily). Morphometric analyses were carried out in each group (n  6 arteries, 18 sections).
Results: Nonanticoagulant E9 inhibited SMC proliferation in vitro. Tyrosine phosphorylation of MAPK 1/2 and MAPK
activity were inhibited with E9 within 5 minutes of incubation. The binding and rapid cytoplasmic internalization of the
synthetic compound was evidenced, but, in contrast to heparin, we did not detect any nuclear localization of the
antiproliferative E9. In the in vivo model, qualitative modifications of neointimal structure with a thinner fibrocellular
neointima were noticed after E9 treatment. Morphometric analyses of stented arteries in E9-treated animals indicated an
important reduction (P < .01) of intimal growth: 33% and 45% for intimal area and intima/media ratio, respectively.
Conclusion: Cytoplasmic internalization of the synthetic polysaccharide correlated to the SMC growth inhibition that
involved the MAPK pathway. In vivo inhibition of intimal instent hyperplasia with this nonanticoagulant derived dextran
is shown providing a new candidate for a potential selective treatment of SMC proliferation. (J Vasc Surg 2002;35:
973-81.)
Accumulation of neointimal smooth muscle cells
(SMCs) that results from medial cell migration and prolif-
eration in response to vascular injury plays a key role in
vascular pathologies, including postangioplasty restenosis.1
Polypeptide growth factors have been identified as activa-
tors of SMC migration and proliferation.2 On the other
hand, heparin3,4 and related synthetic sulfated polysaccha-
rides, such as -cyclodextrin tetradecasulfate5 or pentosan
polysulfate,6 act as inhibitors of SMC growth in vitro and in
vivo. Heparin binds specifically to the SMC membranes7,8
with an unknown receptor and then is internalized.7,9
Heparin interferes with the cell cycle,4 inhibits protoonco-
gene induction,10 binds to extracellular matrix glycopro-
teins11 and to inositol phosphate-activated channels,12 de-
activates metalloproteases,13 and displaces growth factors
from their cellular sites.14 Heparin was shown to inhibit the
activation in SMCs of the mitogen-activated protein kinase
(MAPK) extracellular signal-regulated protein kinase 1/2
(ERK 1/2) induced with serum or thrombin.15-17 Heparin
also has been proposed to act on a nuclear site.18 Different
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trials with heparin to prevent intimal hyperplasia in humans
have failed,19,20 probably because of low local concentra-
tions at the target site.21 This limitation of the dose is
related to the possible hemorrhage side effects and interfer-
ence of this pluripotent polysaccharide with numerous
plasmatic and extracellular heparin-binding factors.22,23
In previous studies, we found that a distribution of
carboxymethyl, benzylamide, and sulfonate/sulfate groups
along a dextran backbone allows the production of syn-
thetic polysaccharides with antiproliferative activity for
SMCs in culture.24,25 Here, we investigated the in vitro and
in vivo SMC growth inhibitory activity of one nonantico-
agulant chemically modified dextran (E9).
MATERIALS AND METHODS
Polysaccharides
Water-soluble derived dextrans were prepared as de-
scribed.24 Native dextran, one carboxymethylated dextran,
and one carboxymethyl benzylamide sulfonated/sulfated
dextran (E9) were tested in this study. Hog intestine hep-
arin (20 kDa; polydispersidy index, 1.3) was purchased
from Sanofi Recherche (Gentilly, France). The derived
dextran E9 was size-fractionated (19 kDa; polydispersidy
index, 1.4). Anticoagulant activities were assessed as previ-
ously described.24 Polysaccharides were fluorolabeled and
radiolabeled with 125I as described.8,9 Tritiated polysaccha-
rides were prepared with 3H sodium borohydride (13.6
Ci/mmol, New England Nuclear, Boston, Mass). Chon-
droitin sulfate was from Sigma (St Quentin Fallavier,
France).
Smooth muscle cell proliferation assays
Thoracic aorta SMCs of Sprague-Dawley rats between
passages 3 and 4 were plated at 1.2  104 cells/well into
24-well plates. After 24 hours, cells were growth arrested
for 48 hours in Eagle’s minimum essential medium
(MEM)  0.4% fetal calf serum (FCS). Cells with or
without native dextran, carboxymethylated dextran, E9, or
heparin added to dishes in quadruplicate at concentrations
ranging from 0.1 to 1000 g/mL were counted daily with
a Coulter counter. The concentration that inhibited cell
growth by 50% (IC50) was determined. SMCs after 24
hours incubation with 100 g/mL of polysaccharides were
pulsed for 1 hour with thymidine (1 Ci/well of 6-[3H]
thymidine). The cell cycle distributions were determined 1
day after the release from the G0 block with serum addition
in the absence or presence of 100 g/mL of polysaccha-
rides. Flow cytofluorimetry was analyzed on a Becton-
Dickinson FacScan II (Le pont de Claix, France).
Western blot analysis
SMCs (1  106) were treated with polysaccharides for
different times in MEM  10% FCS and then lysed as
described.26 Protein concentrations were determined with
the bicinchoninic acid protein assay kit (Pierce, Montluc¸on,
France). Cellular proteins were resolved with sodium do-
decylsulfate–polyacrylamide gel electrophoresis (SDS-
PAGE; 7.5%) and transferred to nitrocellulose membranes
(Hybond enhanced chemiluminescence system; Amer-
sham, Les Ulis, France). Western blots were probed with
the monoclonal antiphosphotyrosine mouse antibody
(4G10; UBI, Orsay, France) and detected with horseradish
peroxidase-coupled antibodies and the enhanced chemilu-
minescence system (Amersham), and the blots were ex-
posed to reflection film (Hyperfilm MP, Amersham).
Assay for mitogen-activated protein kinase activity
Equal quantities of cell lysates from control cells, se-
rum-stimulated cells in 10% FCS alone, or with E9 or
heparin were immunoprecipitated for 16 hours at 4°C
MAPK polyclonal antiserum (erk1-CT; UBI). Immune
complexes were purified with protein A–sepharose. The
precipitate was resuspended in 30 L of kinase assay buffer
(50 mmol/L Tris HCl, pH 7.5, 100 mmol/L NaCl, 10
mmol/L MgCl2, 1 mmol/L dithiothreitol) containing 20
g of myelin basic protein, 50 mol/L adenosine triphos-
phate, and 5 Ci of -32P adenosine triphosphate (ICN,
Orsay, France) for 20 minutes at 30°C, and the assay was
ended with addition of hot 4 SDS-PAGE sample buffer.
Reaction products were resolved with SDS-PAGE (12%),
dried, and subjected to autoradiography.
Binding and displacement of radiolabeled E9 on
smooth muscle cells
Growth-arrested confluent SMCs were cooled to 4°C
for 15 minutes in binding medium (Krebs Ringer solution
supplemented with 0.2% bovine serum albumin and 20
mmol/L N-2-hydroxyethylpiperazine-N-2-ethanesulfon-
ic). Binding and internalization with 2.108 mol/L of
radiolabeled E9 was followed for the indicated times at 4°C
or at 37°C. Three independent experiments were per-
formed each in triplicate wells. Displacements were per-
formed at 4°C in presence of 108 mol/L of radiolabeled
E9 and increasing concentrations of unlabeled polysaccha-
rides. After 1 hour, the cells were washed and lysed and the
amount of radioactivity was determined from the cell ly-
sates.
Autoradiography and electron microscopy
SMC were incubated at 37°C for 15 minutes to 6 hours
with 125I-DTAF-E9 (1 Ci/25 cm2) in MEM 10% FCS,
washed with cold phosphate-buffered saline solution, and
fixed with 1.6% glutaraldehyde in So¨rensen’s phosphate
buffer for 30 minutes, then scraped and pelleted. The
resulting pellets were further dehydrated with ethanol and
included into Epon (Sigma, St Quentin Fallavier, France).
Ultrathin sections were first submitted to autoradiography
as described.25
Preparation of nuclear fractions
Subconfluent growth-arrested SMCs were incubated at
37°C or at 4°C for 6 hours with the radiolabeled (3H or
125I) polysaccharides in MEM  10% FCS. Cells were
detached with trypsin treatment, washed at 4°C, and resus-
pended in 3 mL of buffer A (2 mmol/L MgAc, 3 mmol/L
JOURNAL OF VASCULAR SURGERY
May 2002974 Deux et al
CaCl2, 10 mmol/L Tris HCl, pH 8, 0.5 mmol/L dithiot-
reitol, 1% Triton X 100), and the cell suspension was
homogenized with 20 potter strokes. Buffer B (0.45 mL; 4
mmol/L MgAc, 10 mmol/L Tris HCl, pH 8, 0.5 mmol/L
dithiotreitol, 2 mol/L sucrose) and buffer C (0.45 mL; 3
mmol/L CaCl2, 10 mmol/L Tris HCl, pH 8, 0.5 mmol/L
dithiotreitol, 0.3 mol/L sucrose) were added and homog-
enized with 20 potter strokes. This suspension was layered
over 9 mL of buffer B and centrifuged for 1 hour at
120,000g. The resulting pellet was subsequently washed
three times and resuspended in phosphate-buffered saline
solution.
In vivo protocol. Experimental design complied with
the European Community Standards (Ministe`re de
l’Agriculture, France, Autorization #00577). New Zealand
white rabbits (3.5 to 4 kg) were used in this study. All
animals received a standard diet without cholesterol. Ani-
mals were anesthetized with intravenous pentobarbital, and
the right carotid artery was catheterized with a 5F sheath. A
3.0 mm–diameter, 20 mm–long balloon dilatation catheter
was placed over a standard 0.014-in flexible wire in both
iliac arteries. The iliac arteries were injured by three succes-
sive 1-minute inflations at 10 atm with a 1-minute reflow
after each dilatation. A 15 mm–long balloon-expansible
metallic stent (Helistent, Hexacath, Reuil Malmaison,
France), mounted over the balloon, was implanted in both
iliac arteries immediately after angioplasty (30-second in-
flation at 10 atm), according to the procedure of Feldman
et al.27 Aspirin (50 mg) was given daily to stented animals
in the drinking water. Rabbits received E9 subcutaneously
at the dose of 5 mg/kg or saline solution as control, twice
a day for 14 days.
Tissue harvest and histology processing. Fourteen
days after the procedure, rabbits were killed with injection
of pentobarbital. Blood samples were collected in citrated
tubes. Iliac arteries were perfusion-fixed with 4% parafor-
maldehyde and impregnated in methylmethacrylate. Four-
micron arterial sections were cut with tungsten carbide
knives, mounted on an HM355 motor-driven microtome
(Microm, Waldorf, Germany), and stained with hematox-
ylin-eosin, or orcein. Six arteries were analyzed for control,
and six arteries for E9 treatment. Arteries were divided in
three groups: two at 2 mm from the end of each side of the
artery and one in the middle. From these groups, three
random sections were taken by a blinded observer.
Morphometric analyses. Digital planimetry of
stained arterial sections was performed with the use of a
video camera (IEC 800 CC, I2S Inc, Pessac, France)
mounted on the microscope and an interfaced computer-
assisted image quantification program (Eresilab, ERESI,
Paris, France). The borders of the external elastic lamina,
internal elastic lamina, and vessel lumen were traced on a
digitizing board and the respective areas of intimal and
media were calculated.27
Statistical evaluation. Results are expressed as
mean  standard deviation. Comparisons of histologic
findings between treatment groups were made with the
Fig 1. Antiproliferative effect of E9 on SMC proliferation. A,
Growth-arrested rat SMCs were released from G0 phase with
addition for indicated times of 10% serum in absence (control,
dotted line) or in presence of 100g/mL of E9 () or heparin (f).
Cell numbers were determined, and values of growth inhibition are
expressed as mean  standard deviation of two separate experi-
ments in triplicate. Native dextran (E) and anionic carboxymethyl-
ated dextran (}) were inactive. B, Derived dextran (E9;), native
dextran (E), anionic carboxymethylated dextran (}), and heparin
(f) at indicated concentrations were incubated with SMCs for 5
days. Percent growth inhibition was determined with cell count-
ing. Each point represents average  standard deviation of two
experiments performed in triplicate. C, 3H-Thymidine uptake was
assessed as reported in Materials and Methods section after 24
hours incubation of SMCs with serum (control) or serum  100
g/mL of E9 or heparin. Values of radioactivity in counts per
minute (cpm) represent average  standard deviation in one
representative experiment performed in triplicate. D, Cell cycle
distributions assessed with flow cytofluorimetry were determined 1
day after release from G0 block with serum addition (control) or
serum 100g/mL of E9 or heparin. Values represent average
standard deviation in one representative experiment performed in
triplicate. Statistical analysis for all figure: *P .01 versus control.
**P  .001 versus control.
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unpaired t test. A P value of less than .01 was considered to
be statistically significant.
RESULTS
A derived dextran inhibits smooth muscle cell
growth in culture. A derived dextran (E9), without
significant anticoagulant activity (0.3 IU/mg for E9 versus
173 IU/mg for heparin) inhibited serum-induced
Sprague-Dawley rat SMC proliferation in vitro (Fig 1).
Doubling times assessed with cell counting at day 3 were
51  4 hours for SMCs incubated with 100 g/mL of E9
versus 37  3 hours for untreated cells. After 5 days of
incubation, more than 80% of SMC growth inhibition (P
.001) was obtained (Fig 1, A). The derived dextran E9 and
heparin inhibited, in a time-dependent and dose-dependent
manner, SMC growth, whereas native dextran and anionic
carboxymethylated dextran were inactive (Fig 1, A, B). In
agreement with the inhibition with E9 of 3H-thymidine
uptake at 24 hours (Fig 1, C), we also observed with
microcytofluorimetry that E9 significantly (P  .01) in-
creased after 1 day, the quiescent G0/G1 phase, and de-
creased the proportion of SMCs in the synthesis S phase
(Fig 1, D). Similar growth inhibition with E9 was observed
on cultured vascular SMCs from different species (IC50	 5
to 50g/mL) with potent inhibition values at 100g/mL
of E9 on Wistar rat aorta SMCs (88% 6%), New Zealand
white rabbit aorta SMCs (68%  8%), and human aorta
SMCs (73%  3%), whereas no significant antiproliferative
activity on fibroblasts and endothelial cells was observed
(IC50 
 200 g/mL).
E9 inhibits mitogen-activated protein kinase acti-
vation. We further investigated whether antiproliferative
E9 had an early inhibitory effect on the activation of MAPK
ERK 1/2 proteins. As expected, a 5-minute stimulation of
growth-arrested SMCs with 10% FCS increased the ty-
rosine phosphorylation level of p42/p44 MAPK evaluated
with Western blot analysis (Fig 2, A). Phosphorylation of
p42/p44 bands was maximal 5 minutes after 10% FCS
stimulation and declined thereafter in a time-dependent
manner. Addition of E9 attenuated the tyrosine phosphor-
ylation intensity of the 42/44 kDa protein doublet (Fig 2,
A). Densitometric analysis from three independent experi-
ments shows that E9 treatment significantly (P  .001)
inhibited the FCS-induced MAPK phosphorylation by 67%
 7% after 5 minutes and by 90%  6% after 1 hour.
Indeed, E9 treatment of serum-stimulated SMCs for 1
hour decreased the phosphorylation level of p42/p44
MAPK to a level comparable with serum-unstimulated
cells.
The effect of E9 also was evaluated on MAPK activity,
assessed with the ability of immunoprecipitated MAPK to
phosphorylate radiolabeled myelin basic protein as a sub-
strate. Five minutes after serum addition on quiescent
SMCs (Fig 2, B; lane 1), the activity of MAPK was stimu-
lated 35-fold (lane 2). In contrast, incubation of SMCs for
5 minutes with serum plus heparin (lane 3) or E9 (lane 4)
abolished the stimulatory effect of FCS on MAPK activity
by 90%  7% (P  .001).
Binding and internalization of E9 by smooth mus-
cle cells. A binding/internalization study was carried out
at 4°C and 37°C with radiolabeled E9. The binding of E9
on SMCs at 4°C was saturable (Fig 3). In competition
Fig 2. Inhibition with E9 of MAPK tyrosine phosphorylation (A)
and MAPK activity (B) in serum-stimulated SMCs. A, Quiescent
cells were left untreated or were stimulated for 5 minutes and 1
hour with 10% serum (FCS) with or without E9. SMCs were lysed,
Western blot tests were probed with monoclonal antiphosphoty-
rosine mouse antibody, and equal amounts of cell lysate proteins
were analyzed for p42/p44 MAPK phosphotyrosine content.
Densitometric analysis (arbitrary units) of presented lanes is re-
ported. Results are representative of three independent experi-
ments with significant (*P .001) inhibition in presence of E9. B,
Quiescent SMCs were left untreated (lane 1) or were stimulated for
5 minutes with 10% FCS (lane 2) or with 10% FCS heparin (lane
3) or with E9 (lane 4). Detergent lysates were immunoprecipitated
with anti-MAPK antiserum, and kinase activity was assayed against
radiolabeled myelin basic protein (MBP) in immune complexes.
Reaction mixtures were separated with SDS-PAGE (12%) and
subjected to autoradiography. Position of 14 kDa marker is indi-
cated. Densitometric analysis (arbitrary units) of presented lanes is
reported. Results are representative of three independent experi-
ments with significant (*P  .001) inhibition in presence of
heparin or E9.
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Fig 3. Binding and internalization of E9 into SMCs. SMCs were
incubated for indicated times either at 4°C () or at 37°C ()
with radiolabeled E9. Cells then were washed, and amount of
bound radioactivity was determined from cell lysates. Each point
represents mean standard deviation of three values. cpm, Counts
per minute.
Fig 5. Internalization of E9. Representative electron micrographs of SMCs after autoradiography show E9 distribu-
tions when adherent cells were incubated at 37°C with radiolabeled E9 (1 Ci) for 15 minutes (A), 1 hour (B), and 6
hours (C). Black arrows show isolated (A) or grouped (B,C) radiolabeled E9 located next to plasma membrane and in
endosomes. Silver grains were not found associated with nuclei. Original magnification,12,000 (A,C); and15,000
(B). N, Nucleus.
Fig 4. Displacement experiments of SMC bound radiolabeled
E9. Confluent cultures of SMCs were incubated for 4 hours at 4°C
with radiolabeled E9 (10 nmol/L/dish) in presence of increasing
concentrations of unlabeled E9 (), heparin (f), native dextran
(), anionic carboxymethylated dextran (}), or chondroitin sul-
fate (Œ). Cells were washed, and amount of bound radioactivity
was determined from cell lysates. Average of three values are
indicated. Standard deviation for all points was less than 10% of
mean value.
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binding studies at 4°C, unlabeled E9 or heparin displaced
radiolabeled E9 bound to SMCs (Fig 4). In contrast, native
dextran, anionic carboxymethylated dextran, or chon-
droitin sulfate, all inactive polysaccharides on SMC growth,
were unable to displace bound E9 (Fig 4). In addition to
the binding, we observed at 37°C the increase with time of
radioactivity associated with cells (Fig 3; upper curve),
suggesting the continuous internalization of E9 into
SMCs.
SMCs also were incubated with radiolabeled E9 and
analyzed with electron microscopy after autoradiography.
Fig 5 represents a panel of electron micrographs of SMCs
incubated at 37°C for 15 minutes, 1 hour, and 6 hours with
E9. As early as 15 minutes in serum supplemented media,
surface-bound E9 was visualized and a small amount of
polysaccharide was already detected in intracellular vesicles
(Fig 5 , A). After 1 hour of incubation, silver grains were
clearly seen (Fig 5, B). After 6 hours of incubation, inter-
nalized polysaccharide had accumulated in large vesicles
located around the nucleus (Fig 5, C) indicating that SMCs
were capable of a selective internalization of E9.
We then checked with cell fractionation the possible
SMC nuclear internalization of the radiolabeled polysac-
charide. The SMCs were serum-deprived, subsequently
incubated in presence of serum with tritiated or iodinated
E9 for 6 hours at 4°C (to prevent internalization) or at
37°C, and then subjected to cell fractionation. The lack of
radioactivity in the nuclear pellets indicated no significant
nuclear labeling of SMCs incubated at 37°C with 3H-E9 or
125I-E9 (Table I). In contrast, SMCs incubated with radio-
labeled heparin at 37°C for 6 hours (Table I) exhibited a
significant (P  .005) nuclear labeling representing 1 ng/
105 cells for nuclear preparations (membranes  nuclear
content).
E9 inhibits intimal hyperplasia in vivo. We tested,
in a model of angioplasty followed by stent implantation,
the effect of E9 on injured iliac arteries. No rabbits died
during the 14 days of treatment. No bleeding or hemato-
logic changes on blood samples between the E9-treated
group and the control group were observed (data not
shown). Arterial cross-sectional area in stented animals, a
marker of arterial stretching, was not different in the E9-
treated group and in the control group (5.99  0.50 mm2
and 5.34  0.87 mm2, respectively; not significant). Me-
dial area was also similar between E9-treated and control
groups (Table II), indicating that E9 was not affecting the
arterial stretching in this animal model. However, a neoin-
timal covering had developed in the arteries in the internal
elastic lamina (Fig 6) that was of high cell density in the
control group (Fig 6, A). As expected, the intimal area was
significantly greater in the control group (Fig 6, A) than in
the E9-treated group (Fig 6, B). Morphometric analyses (in
each group: n 	 6 arteries, 18 sections) indicated a signif-
icant reduction (P  .01) of intimal growth in E9-treated
animals by 33%  11%, 40%  13%, and 45%  19% for
intimal area, luminal cross-sectional area narrowing, and
intima/media ratio, respectively (Table II). Interestingly,
we also observed qualitative modifications of neointimal
structure with E9 treatment. The decrease in the thickness
of the neointima induced with E9 treatment was associated
with an improvement in the vessel wall architecture, with a
reduced number and a better organization of the cell layers
associated with a reduction of neointimal matrix proteins
(Fig 6, B) as compared with controls (Fig 6, A).
DISCUSSION
The purpose of this study was to investigate the growth
inhibition on vascular SMCs in vitro and in vivo with a
chemically modified dextran of similar molecular weight to
heparin. We used a synthetic polysaccharide (E9) devoid of
risk of contamination of animal origin and devoid of anti-
coagulant activity (1/500 the one of heparin). We first
observed that the antiproliferative activity of E9 on SMCs
in culture was important and similar to heparin. The effects
with E9 were dose-dependent, reversible, and noncyto-
toxic, and the cells were blocked in the G0/G1 phase as
soon as they entered the cell cycle after serum stimulation.
Table I. Radioactivity in nuclear extracts after incubation
of intact SMCs with E9 or heparin
Nuclear labeling (cpm / g protein)
3H-polysaccharides 125I-polysaccharides
E9 (4°C) 3  0.5 67  27
Heparin (4°C) 8  2 115  35
E9 (37°C) 10  6 173  100
Heparin (37°C) 42  7* 869  49*
SMCs (2.5  106 cells) were incubated for 6 hours at 4°C (control: cell
binding) or at 37°C (binding  internalization) with 1 Ci of 3H-polysac-
charides or 125I-polysaccharides. Nuclear extracts were obtained after ultra-
centrifugation as described in Materials and Methods section. Nuclear
protein concentration was determined, and results in cpm/g protein are
expressed as mean  standard error of two experiments for 3H-polysaccha-
rides and three experiments for 125I-polysaccharides, each performed in
duplicate.
*Indicates significantly different (P .005) from experiments performed at
4°C.
cpm; Counts per minute.
Table II. Morphometric analyses of rabbit iliac arteries
after 14 days of treatment with E9
Control E9
Intima (mm2) 1.82  0.50 1.22  0.20 (P  .01)
Media (mm2) 0.40  0.04 0.49  0.09 (P 	 NS)
Intima/media 4.54  1.42 2.51  0.92 (P  .01)
Intima/IEL 0.37  0.08 0.22  0.05 (P  .005)
Iliac arteries were injured with balloon inflation, and metallic stent was
mounted over balloon. Saline solution (as control) or E9 at 5 mg/kg was
injected subcutaneously twice daily for 14 days. In each group (n 	 6
arteries), 18 sections were analyzed. Borders of external elastic lamina,
internal elastic lamina (IEL), and vessel lumen were calculated together with
respective areas of intima and media. Intimal growth was estimated with
intimal area, ratio of intimal to medial areas, and ratio of intimal area to
area bounded by IEL (luminal cross-sectional area narrowing).
NS, Not significant.
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We also investigated the effect of E9 on MAPK activation.
It is known that activation by mitogens of MAPKs during
the G1 progression triggers the entry into S phase of the cell
cycle28 and that heparin prevents G0-arrested SMCs from
entering the cell cycle and inhibits MAPK ERK1/2 activity
on vascular cultured SMCs in response to different mito-
gens.15-17,29 We show here that E9 inhibited both MAPK
tyrosine phosphorylation and MAPK activity as early as 5
minutes after serum stimulation of G0-arrested SMCs (Fig
2). Thus, antiproliferative E9 induced a rapid inhibitory
effect via the MAPK pathway on serum-induced SMCs.
Because MAPKs are translocated into the nucleus
within 15 minutes, one could speculate that cytosolic or
nuclear MAPK activation could be directly inhibited with
E9. It is thus interesting to note that after the binding with
saturable and displaceable membrane sites, a rapid (5 to 15
minutes) uptake with SMCs occurred for the synthetic
polysaccharide under conditions consistent with the inhi-
bition of proliferation (IC50 concentration range and se-
rum stimulation on growth-arrested SMCs). Internaliza-
tion of fluorescent and radiolabeled E9 in SMCs was
evidenced with electronic autoradiography and with con-
focal microscopy (data not shown). However, E9 was
found neither in the nuclear preparations nor at the level of
nuclei or associated with nuclear membranes (see Fig 5, C,
as an example of more than 100 examinations) on the
autoradiographic experiments.
Consequently, SMC growth inhibition with E9 cannot
be directly attributed to a nuclear site of action. In contrast,
we observed a small but significant amount of heparin that
reached the nuclear area. Indeed, Barzu et al30 with triti-
ated heparin in SMCs and autoradiography observed sparse
silver grains also at the level of the nuclear membrane.
Heparan sulfates also were transported to the nucleus in
hepatocytes.31 Our results indicated that the binding and
cytoplasmic internalization of E9 appear to correlate with
the inhibition of cytosolic ERK 1/2 activation in serum-
stimulated SMCs.
Potent mitogens for SMCs need cell surface heparan
sulfate proteoglycans as coreceptors, and heparin inhibited
signaling events induced by growth factors.15-17,29 The
inhibitory effect of E9 on serum-induced ERK 1/2 activa-
tion and SMC proliferation may be partly accounted for by
a blockade of soluble forms of growth factors. We and other
investigators have recently reported that nonsulfated de-
rived dextrans bearing anionic carboxylic groups and hy-
drophobic aromatic moieties were able to interact with
heparin-binding growth factors such as vascular endothelial
growth factor 165, fibroblast growth factor–2 (FGF2),
platelet-derived growth factor, and transforming growth
factor–.32-34 Spatial distribution of chemical groups in
relation to stiffness and molecular weight of E9 may form
complexes with growth factors and their receptors, thus
decreasing the mitogenic response. In this context, Liekens
et al35 showed that synthetic sulfonic polymers with aro-
matic rings were able to interfere with FGF2 activity,
leading to a reduced ERK 1/2 activation on endothelial
cells. Similarly, Miao et al36 have used a synthetic nonsul-
fated polyanionic aromatic compound and found a direct
interaction with FGF2. This compound inhibits SMC pro-
liferative response to growth factors and exhibits binding to
vascular SMCs that is not competed with heparin.37 In
contrast, the binding and internalization of E9 via a mem-
brane receptor sharing heparin-binding motifs (Fig 4) is in
favor of a receptor-mediated mechanism, leading to the
inhibition of signal transduction events. The binding and
rapid uptake of E9 in SMCs could be the result of an
appropriate distribution of aromatic and anionic (carboxyl,
sulfate, and sulfonate) groups in E9 revealing an active
conformation. Then, one appealing hypothesis is that the
internalized E9 may interfere with the kinase cascade trans-
mitting growth factor signals. ERK 1/2 inhibition with E9
within 5 minutes of treatment thus could be tentatively
linked to rapid gene regulation.38 It is also important to
note that SMC hyperplasia occurs in response to growth
factors that stimulate G protein–coupled receptors and
tyrosine kinase–coupled receptors.39 Early events on these
receptors, such as activation of Janus kinase and TYK
kinases,39 Ras40 and Raf,41 might be responsible for the
inhibition with E9 of MAPK activation in response to
serum. It thus could be proposed that an extracellular
action of E9 on the blockade of growth factors and their
receptors may act in synergy with intracellular events in
SMCs. Future work will be directed to determine the effect
of E9 on pathways shared by G protein–coupled receptors
and tyrosine kinase receptors.
The potent antiproliferative activity of the nonantico-
agulant E9 on SMCs in culture had to be challenged in vivo
Fig 6. E9 inhibits SMC hyperplasia after balloon angioplasty and stenting. Photomicrographs with hematoxylin eosin
staining of injured rabbit iliac arteries after 14 days in control animals (A) or in E9-treated animals (B). Cross-sectional
analysis (Table II) revealed significant (P  .01) difference in lumen and intimal area within two groups. Original
magnification, 33 (A,B). Arrow indicates intima thickness. s, Stent; a, adventice; m, media; i, intima.
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because the main stimuli implicated in restenosis are dis-
ruption of the endothelial barrier layer, direct contact of
proliferating SMCs with circulating blood factors and mi-
togens, and mechanical factors. We thus assessed the effect
of E9 on rabbits in a model of iliac artery restenosis induced
with balloon deendothelialization followed by stent im-
plantation after balloon dilatation.27,42 Morphometric
analyses performed 14 days after balloon angioplasty injury
and stenting indicated that E9 reduced intimal growth by
30% to 50%, resulting in more preserved lumen dimensions
in treated arteries. Moreover, no toxic effect or changes in
hematologic parameters were detected after treatment with
E9. In the treated arteries, we also noticed a reduced
number and a better organization of the cell layers, leading
to an important decrease in extracellular matrix accumula-
tion in the intima. We thus conclude from the in vivo
experiments that the synthetic compound reduces postin-
jury intimal hyperplasia in this model of restenosis.
Taken together, our in vitro results indicate that the
antiproliferative effect of a synthetic nonanticoagulant de-
rived dextran appears to occur via a pathway including
MAPK activation and may be linked to its binding and
internalization in SMCs. These effects may be relevant in
growth-regulation signaling pathways in response to serum
and G protein–coupled receptors.39 Additional experi-
ments will be devoted to the study of upstream and down-
stream cascades of events involved in the SMC control of
growth. Nevertheless, our results in the rabbit model of
balloon angioplasty and stenting already raise the possibility
of using E9 in the prevention of instent restenosis. Future
experiments will investigate the potency of this type of
compound with local delivery systems within the injured
vessel walls or for the coating of vascular prosthetic devices.
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